AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

VENTURE LIFE GROUP PLC

Net Asset Value May 23, 2018

8004_agm-r_2018-05-23_05faa864-0e31-4fdf-8afc-3648790eda3c.html

Net Asset Value

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0531P

Venture Life Group PLC

23 May 2018

23 May 2018

Venture Life Group plc

("Venture Life" or "the Company")

Result of AGM

Venture Life (AIM: VLG), the international consumer self-care company focused on developing, manufacturing and commercialising products for the self-care market, announces that at its Annual General Meeting held earlier today, all resolutions were duly passed.

Enquiries

Venture Life Group PLC +44 (0) 1344 742870
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Northland Capital Partners Limited (Nominated Adviser and Joint Broker) +44 (0) 20 3861 6625
Matthew Johnson / Edward Hutton (Corporate Finance)
John Howes / Vadim Alexandre (Corporate Broking)
Turner Pope Investments (TPI) Ltd (Joint Broker) +44 (0) 20 3621 4120
James Pope / Ben Turner
Walbrook PR [email protected] or + 44 (0) 20 7933 8780
Anna Dunphy /Paul McManus +44 (0) 7876 741 001 / +44 (0) 7980 541 893

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population.  The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners. 

Through its Development and Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

RAGUOUARWWAVUAR

Talk to a Data Expert

Have a question? We'll get back to you promptly.